Lisa M. Krieger, The Mercury News; Coronavirus: The global race to patent a remedy
"As a lethal coronavirus triggers a humanitarian crisis in the world’s
most populous nation, who owns the rights to a potential cure?
The Bay Area’s pharmaceutical powerhouse Gilead Sciences is first in
line for a Chinese patent for its drug called Remdesivir, which shows
promise against the broad family of coronaviruses.
But now a team of Chinese scientists say they’ve improved and
targeted its use — and, in a startling move, have also filed for a
patent...
“Each side wants to be the entity that came up with the treatment for
coronavirus,” said Jacob Sherkow, professor of law at the Innovation
Center for Law and Technology at New York Law School. “This is not a
knockoff of a Louis Vuitton handbag,”...
Patent protection — and market exclusivity — is the lifeblood of drug
companies such as Gilead, creating the incentive to find, test and
market a medicine."
Issues and developments related to ethics, information, and technologies, examined in the ethics and intellectual property graduate courses I teach at the University of Pittsburgh School of Computing and Information. My Bloomsbury book "Ethics, Information, and Technology" will be published in Summer 2025. Kip Currier, PhD, JD
Showing posts with label humanitarian crises. Show all posts
Showing posts with label humanitarian crises. Show all posts
Friday, February 14, 2020
Coronavirus: The global race to patent a remedy; The Mercury News, February 13, 2020
Subscribe to:
Posts (Atom)